GH Research

GHRS · Nasdaq · Ireland

Share price · GHRS

$18.25-11.48 (-38.62%) 3M

close as of 2026-11-18 · 24h delayed · vol 462K (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GHRS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 26 Oct 2026+6.1%

    Nothing announced by GHRS that day or the session before.

  2. 24 Sep 2026-5.8%
  3. 16 Jul 2026+8.2%

    Nothing announced by GHRS that day or the session before.

  4. 26 Jun 2026+11.4%
  5. 24 Apr 2026+7.7%

    Nothing announced by GHRS that day or the session before.

  6. 22 Apr 2026-8.2%

    Nothing announced by GHRS that day or the session before.

  7. 20 Apr 2026+17.2%
  8. 8 Jan 2026-13.4%
  9. 7 Jan 2026+27.1%

    Nothing announced by GHRS that day or the session before.

  10. 6 Jan 2026-8.7%

Share of unusual movement by asset

For each asset, the share of GHRS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Mebufotenin (5-MeO-DMT) (GH001)
events and moves
1337%
Other company news (earnings, financing, releases naming no asset)—12%
Sessions with no dated event—51%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
5-HT2A receptorSmall molecule
Major Depressive Disorder

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3—$11M$250M$14M-$14M operating cash flowreport ↗

GH Research reported no revenue for Q3 2025, with R&D spend of $10.57M, up 25.8% YoY from $8.4M. Cash and equivalents stood at $249.65M, and the company posted a net loss and quarterly net burn of $14.02M.

The company presented Phase 2b data for GH001, a synthetic mebufotenin inhalation therapy, in treatment-resistant depression. The trial met its primary endpoint, and secondary endpoints showed significant improvements in illness severity, anxiety symptoms, and quality of life at Day 8, with durable effects maintained at Month 6 in the open-label extension. No financial guidance was disclosed.

View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2—$9.0M$254M$9.3M-$9.0M operating cash flowreport ↗
2025-Q1—$7.8M$245M$11M-$8.6M operating cash flowreport ↗
2024-Q3—$8.4M$90M$12M-$12M operating cash flowreport ↗
2024-Q2—$9.8M$87M$10M-$9.9M operating cash flowreport ↗
2024-Q1—$8.7M$77M$7.7M-$9.6M operating cash flowreport ↗
2023-Q3—$7.1M$86M$5.7M-$10M operating cash flowreport ↗
2023-Q2—$7.2M$97M$7.7M-$8.0M operating cash flowreport ↗
2023-Q1—$7.3M$105M$11M-$6.9M operating cash flowreport ↗
2022-Q3—$4.6M$257M$0.4M-$8.0M operating cash flowreport ↗
2022-Q2—$4.2M$265M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$39M$246M$12M-$44M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$35M$101M$9.7M-$42M operating cash flowreport ↗
2023-FY—$30M$78M$8.9M-$33M operating cash flowreport ↗
2022-FY—$20M$166M$5.6M-$26M operating cash flowreport ↗
2021-FY—$8.6M$277M$2.3M-$15M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-08Schonharting Florian · directorAward / grant (derivative)2,303——Form 4
2026-08-11Forer Michael · directorAward / grant (derivative)2,202——Form 4
2026-08-11Hanley Dermot John · directorAward / grant (derivative)2,202——Form 4
2026-08-11Moore Duncan · directorAward / grant (derivative)2,202——Form 4
2026-08-11Forer Michael · directorAward / grant (derivative)100,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 53 reporting institutions held 47.6M shares ($668.5M, 76.7% of shares outstanding).

#InstitutionSharesValue
1Lynx1 Capital Management LP10,763,288$151.3M
2BVF INC/IL8,650,158$121.6M
3RA CAPITAL MANAGEMENT, L.P.7,676,697$107.9M
4RTW INVESTMENTS, LP5,933,815$83.4M
5FMR LLC5,136,045$72.2M
6Avoro Capital Advisors LLC1,800,000$25.3M
7TORONTO DOMINION BANK1,397,873$19.7M
8Troluce Capital Advisors LLC990,472$13.9M
9MILLENNIUM MANAGEMENT LLC937,898$13.2M
10Jefferies Financial Group Inc.712,300$10.0M
115AM Venture Management, LLC572,665$8.1M
12BlackRock, Inc.455,618$6.4M
13UBS Group AG412,416$5.8M
14Squadron Capital Management LLC325,000$4.6M
15Foresite Capital Management VI LLC315,492$4.4M